Exploring DRD4 and its interaction with SLC6A3 as possible risk factors for adult ADHD: A meta-analysis in four European populations by Sánchez-Mora, C. et al.
RESEARCH ARTICLE
Exploring DRD4 and Its Interaction With SLC6A3 as
Possible Risk Factors for Adult ADHD: A Meta-Analysis
in Four European Populations
Cristina Sanchez-Mora,1,2,3 Marta Ribases,1,2 Miquel Casas,1,4 Monica Bayes,5 Rosa Bosch,1,4
Noelia Fernandez-Castillo,3,6 Lucas Brunso,3 Kaya K. Jacobsen,7,8 Elisabeth T. Landaas,7,8
Astri J. Lundervold,9 SilkeGross-Lesch,10 SusanneKreiker,11 Christian P. Jacob,10Klaus-Peter Lesch,10
Jan K. Buitelaar,12 Martine Hoogman,13 Lambertus A.L.M. Kiemeney,14 J.J. Sandra Kooij,15 Eric Mick,16
Phil Asherson,17 Stephen V. Faraone,18 Barbara Franke,13,19 Andreas Reif,10 Stefan Johansson,7,8
Jan Haavik,8,20 Josep Antoni Ramos-Quiroga,1,4 and Bru Cormand3,6,21*
1Department of Psychiatry, Hospital Universitari Vall d’Hebron, Barcelona, Catalonia, Spain
2Psychiatric Genetics Unit, Hospital Universitari Vall d’Hebron, Barcelona, Catalonia, Spain
3Facultat de Biologia, Departament de Genetica, Universitat de Barcelona, Catalonia, Spain
4Department of Psychiatry and Legal Medicine, Universitat Autonoma de Barcelona, Catalonia, Spain
5Centro Nacional de Analisis Genomico (CNAG), Parc Cientıﬁc de Barcelona (PCB), Catalonia, Spain
6CIBER Enfermedades Raras, Barcelona, Catalonia, Spain
7Department of Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
8Department of Biomedicine, University of Bergen, Bergen, Norway
9Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway
10Department of Psychiatry, Psychosomatics and Psychotherapy, University of W€urzburg, W€urzburg, Germany
11Department of Child and Adolescent Psychiatry and Psychotherapy, University of W€urzburg, W€urzburg, Germany
12Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands
13Department of Psychiatry, Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen Medical Centre, Nijmegen,
The Netherlands
14Department of Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Additional Supporting Information may be found in the online version of this article.
Grant sponsor: ‘‘InstitutodeSaludCarlos III-FIS,’’ Spain;Grantnumbers:PI040524PI041267,PI080519;Grant sponsor: ‘‘FundacioLaMaratodeTV3’’;Grant
number: 092330/31; Grant sponsor: ‘‘Agencia de Gestio d’Ajuts Univeristaris i de Recerca-AGAUR’’; Grant number: 2009SGR-00971; Grant sponsor: Obra
Social - Fundacio ‘‘LaCaixa’’; Grant number: 2007-2010;Grant sponsor: SubdireccioGeneral deDrogodependencies,Departament de Salut, andPlaDirector
de SalutMental i Addiccions, CataloniaGovernment (Generalitat deCatalunya); Grant sponsor:HersenstichtingNederland (Fonds PsychischeGezondheid);
Grant sponsor: ResearchCouncil ofNorway; Grant sponsor:WesternNorwayRegionalHealthAuthority;Grant sponsor: TheNational ResearchNetwork for
ADHD; Grant sponsor: The University of Bergen; Grant sponsor: DFG; Grant numbers: RE1632/1-5, KFO 125 SFB TRR 58/A1,5, Z02, GRK 1156; Grant
sponsor: GK Emotions; Grant sponsor: BMBF; Grant number: 01GV0605; Grant sponsor: EC; Grant number: NEWMOOD LSHM-CT-2003-503474.
Conﬂict of interest:Netherlands: In thepast 3 years, JanK.Buitelaar has beena consultant to/memberof advisory boardof and/or speaker for JanssenCilagBV,
Eli Lilly, Bristol-Myer Squibb, Organon/Shering Plough, UCB, Shire,Medice, and Servier. He is not an employee of any of these companies. He is not a stock
shareholderof anyof these companies.Hehasnootherﬁnancial ormaterial support, includingexpert testimony,patentsor royalties. SandraKooij has received
research grants from JanssenBVenShire, and is on the speaker’s bureauof Janssen andEli Lilly.MartineHoogman, LambertusKiemeney, andBarbara Franke
declareno conﬂicts of interest.Norway: JanHaavikhas beena consultant for JanssenCilag andNovartis. Authors fromGermany andSpaindeclareno conﬂicts
of interest.
Barbara Franke, Andreas Reif, Stefan Johansson, Jan Haavik, Josep Antoni Ramos-Quiroga, and Bru Cormand contributed equally to this study.
*Correspondence to:
Dr. Bru Cormand, Associate Professor of Genetics, Facultat de Biologia, Departament de Genetica, Universitat de Barcelona, Av. Diagonal 645, Ediﬁci
Annex, 3a Planta, 08028 Barcelona, Spain. E-mail: bcormand@ub.edu
Published online 18 May 2011 in Wiley Online Library
(wileyonlinelibrary.com).
DOI 10.1002/ajmg.b.31202
 2011 Wiley-Liss, Inc. 600
Neuropsychiatric Genetics
15PsyQ, Psycho-Medical Programs, Program Adult ADHD, The Hague, The Netherlands
16Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
17MRC Social Genetic Developmental and Psychiatry Centre, Institute of Psychiatry, London, UK
18Department of Psychiatry and Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, New York
19Department of Human Genetics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
20Department of Psychiatry, Haukeland University Hospital, Bergen, Norway
21Institut de Biomedicina de la Universitat de Barcelona (IBUB), Catalonia, Spain
Received 24 November 2010; Accepted 25 April 2011
Attention-deﬁcit hyperactivity disorder (ADHD) is a common
behavioral disorder affecting about 4–8% of children. ADHD
persists into adulthood in around 65% of cases, either as the full
condition or in partial remission with persistence of symptoms.
Pharmacological, animal and molecular genetic studies support
a role for genes of the dopaminergic system in ADHD due to its
essential role in motor control, cognition, emotion, and reward.
Based on these data, we analyzed two functional polymorphisms
within the DRD4 gene (120 bp duplication in the promoter and
48 bp VNTR in exon 3) in a clinical sample of 1,608 adult ADHD
patients and 2,352 controls of Caucasian origin from four
European countries that had been recruited in the context of
the International Multicentre persistent ADHD CollaboraTion
(IMpACT). Single-marker analysis of the two polymorphisms
did not reveal association with ADHD. In contrast, multiple-
markermeta-analysis showedanominal association (P¼ 0.02)of
the L-4R haplotype (dup120bp-48bpVNTR) with adulthood
ADHD, especially with the combined clinical subtype. Since we
previously described association between adulthood ADHD and
the dopamine transporter SLC6A3 9R-6R haplotype (30UTR
VNTR-intron 8 VNTR) in the same dataset, we further tested
for gene gene interaction between DRD4 and SLC6A3. How-
ever, we detected no epistatic effects but our results rather
suggest additive effects of the DRD4 risk haplotype and the
SLC6A3 gene.  2011 Wiley-Liss, Inc.
Key words: attention-deﬁcit hyperactivity disorder; case–
control association study; neurotransmission; dopamine;
psychiatric genetics
INTRODUCTION
Attention-deﬁcit hyperactivity disorder (ADHD) is a common
behavioral disorder affecting 4–8% of children [Polanczyk et al.,
2007] and is characterized by inappropriate and impairing levels of
hyperactivity, impulsivity, and inattention. ADHD persists into
adulthood in around 65% of cases either as the full condition or in
partial remissionwith persistence of symptoms andwith signiﬁcant
clinical impairment [Faraone et al., 2006; Lara et al., 2009]. A review
of 20 twin studies in children estimated the heritability of ADHD to
be around 76% [Faraone et al., 2005; Faraone and Mick, 2010].
Pharmacological studies, animal models, and molecular genetic
studies support a role for genes of the dopamine, serotonin, and
norepinephrine neurotransmitter systems in ADHD. Research,
however, has mainly focused on the dopaminergic system due to
its essential role in motor control, cognition, and reward. In this
regard, magnetic resonance imaging suggests abnormalities in
ADHD-affected children in neuro-anatomical areas rich in dopa-
minergic innervations [Ernst et al., 1999; Durston et al., 2005]. In
addition,methylphenidate, amphetamine, and other psychostimu-
lant drugs increase synaptic levels of dopamine and are effective in
the control ofADHDsymptoms through blockade of the dopamine
transporter.
Among the different genes involved in dopaminergic neuro-
transmission, the dopamine receptor D4 (DRD4) has been widely
considered in genetic studies of ADHD. The DRD4 gene is located
at chromosome 11p15.5, organized in 4 exons and encodes a
G-protein-coupled receptor belonging to the dopamine D2-like
receptor family. This family of receptors is expressed predominant-
ly in the prefrontal cortex. DRD4 contains a number of poly-
morphisms, one of which, a variable number of 48 bp tandem
repeats (48bpVNTR), is located in the third exon of the gene. This
exon encodes the putative third cytoplasmic loop of the receptor
and modulates the receptor’s signal transduction properties by
altering intracellular cyclic AMP levels [Van Tol et al., 1992]. This
polymorphism, with a unit that is repeated from 2 (2R) to 11 (11R)
times, shows considerable inter-ethnic heterogeneity [Van Tol
et al., 1992; Chang et al., 1996]. Although its effect on the DRD4
function is still unknown, different pharmacological properties
have been described for the distinct repeat lengths, with the 7R allele
dampening the response of cells to dopamine [Asghari et al.,
1995]. Other studies, however, showed no evidence of quantitative
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differences in G-protein coupling among theDRD4 2R, 4R, and 7R
alleles [Kazmi et al., 2000].
Since the publication of the initial study by LaHoste et al. [1996]
showing association between the 7R allele of the 48bpVNTR and
ADHD in children, many case–control and family-based associa-
tion studies have been reported, although they show controversial
results. After the ﬁrst studies that identiﬁed the 7R as a risk allele for
ADHD, most of the subsequent work solely tested this allele versus
all the others [Castellanos et al., 1998; Comings et al., 1999; Muglia
et al., 2000; Tahir et al., 2000; Curran et al., 2001; Mill et al., 2001;
Langley et al., 2004; Gabriela et al., 2009]. Other studies differenti-
ated between short (2R–5R) and long alleles (6R–11R) [Eisenberg
et al., 2000; Hawi et al., 2000; Kotler et al., 2000;Manor et al., 2002].
However, only some of these studies focused on adult ADHD
[Muglia et al., 2000; Smith et al., 2003; Johansson et al., 2008].
Johansson et al. [2008] found no association between the DRD4
VNTR polymorphism and adulthood ADHD. On the other hand,
Muglia et al. [2000] suggested a role of the 7R allele in adult ADHD
and, ﬁnally, although performed in childhood ADHD samples,
several meta-analyses have demonstrated a signiﬁcant association
between thisDRD4 allele and ADHD [Faraone et al., 2001; Faraone
et al., 2005; Li et al., 2006; Gizer et al., 2009; Nikolaidis and Gray,
2010; Smith, 2010].However, some of thesemeta-analyses detected
signiﬁcant heterogeneity in the effect size forDRD4 in the different
studies [Li et al., 2006; Gizer et al., 2009; Smith, 2010].
Seaman et al. [1999] subsequently identiﬁed a second common
genetic variant in DRD4, the 120 bp duplication (dup120bp)
located 1.2 kb upstream of the DRD4 translation initiation codon.
The duplication contains consensus sequences for several tran-
scription factors andmodulates transcription of theDRD4 gene. In
this regard, the 240 bp allele (long or L allele) showed enhanced
binding capacity for the Sp1 transcription factor in a mobility shift
assay and exhibited lower transcriptional activity than the 120 bp
allele (short or S allele) in transfected cell lines [D’Souza et al., 2004;
Ronai et al., 2004;Kereszturi et al., 2007]. Several studies have tested
association between the DRD4 dup120bp polymorphism and
ADHD but results are also controversial, showing no association
[Barr et al., 2001; Todd et al., 2001; Brookes et al., 2005; Bhaduri
et al., 2006;Gizer et al., 2009] or identifying either theLor S alleles as
risk factors for ADHD [McCracken et al., 2000; Kustanovich et al.,
2004; Kereszturi et al., 2007]. Accordingly, a recent meta-analysis
performed by Gizer et al. [2009] found no association between
childhood ADHD and either allele. So far, Arcos-Burgos et al.
[2004] were the only researchers to study the role of a haplotype of
both polymorphisms in ADHD and indeed found signiﬁcant
evidence for association with the S-7R DRD4 haplotype.
Since both the 48bpVNTR and the dup120bp polymorphisms in
DRD4may affect the receptor function through changes in amino
acid sequence or promoter activity and to challenge the incon-
sistencies raised among previous case–control and family-based
association studies, we aimed to investigate the possible involve-
ment of these polymorphisms in ADHD in a large sample of adult
patients and controls from Europe. We performed a meta-analysis
of unpublished case–control data from four different countries
(Germany, The Netherlands, Norway, and Spain) integrated in the
International Multicentre persistent ADHD CollaboraTion
(IMpACT) in a sample of 1,608 adult ADHD patients and 2,352
controls. Also, as several studies have shown epistatic [Roman et al.,
2001; Gabriela et al., 2009] or additive effects [Carrasco et al., 2006]
between DRD4 and SLC6A3 in ADHD or hyperactive-impulsive
symptoms [Auerbach et al., 2010], we used previously published
SLC6A3 genotype data from IMpACT [Franke et al., 2010] to assess
their potential combined contribution to adulthood ADHD.
MATERIALS AND METHODS
Patients and Controls
In total, 1,608 adult ADHD patients and 2,352 controls of Cauca-
sian origin from four European countries (Spain, Germany, Nor-
way, and The Netherlands) were recruited at four sites of IMpACT.
Table I shows the clinical description of these patient cohorts.
Diagnosis was blind to genotype. The study was approved by the
ethics committee of each participating institution and informed
consent was obtained from all subjects in accordance with the
Helsinki Declaration.
Consensus eligibility criteria for the current study across all sites
were a diagnosis of ADHD according to the diagnostic criteria
of Diagnostic and Statistical Manual for Mental Disorders-IV
(DSM-IV), onset before the age of 7 years via retrospective
diagnosis (which was conﬁrmed by a family member, wherever
possible), lifelong persistence, and current diagnosis. Patients were
extensively examined by psychiatrists experienced in adult ADHD
and were evaluated for other psychiatric disorders with the Struc-
tured Clinical Interview of DSM-IV for axis-I (and axis-II) dis-
orders (SCID-I, SCID-II) or semi-structured interviews. Most
controls (except for theNorwegian samples and part of theGerman
samples)were screened for thepresenceofADHDand those scoring
high on symptoms of the disorder were excluded (for a more
detailed description of the different diagnostic instruments, see
Sanchez-Mora et al., 2010).
DNA Isolation and Genotyping
Genomic DNA was isolated either from saliva using the Oragene
DNA Self-Collection Kit (DNA Genotek Inc., Ottawa, Ontario,
Canada) or from peripheral blood lymphocytes by the salting-out
procedure [Miller et al., 1988].
Dup120bp DRD4 polymorphism. Genotyping was carried out
using standard PCR methods and ampliﬁcation products were
tested by electrophoresis on a 1.5% agarose gel and ethidium
bromide staining (Germany, Spain, and The Netherlands) or
visualized on anABI 3100 sequencer and automatically called using
the GeneMapper software (Applied Biosystems, Foster City, CA).
Genomic DNA was ampliﬁed with primers 50-GTTGTCT-
GTCTTTTCTCATTGTTTCCATTG-30 and 50-GAAGGAGCAGG-
CACCGTGAGC-30 for the Spanish, German, and Dutch samples
and with a ﬂuorescently labeled (FAM) reverse primer for the
Norwegian samples. For the German, Spanish, and Norwegian
samples, PCR reactions were carried out in a ﬁnal volume of 10ml,
l, containing 5 ng of genomic DNA, 0.5 pmol of each primer, 1ml
PCRxEnhancer solution (10; PCRxEnhancer System, Invitrogen,
Breda, The Netherlands), 1ml PCRx Ampliﬁcation Buffer (PCRx
Enhancer System, Invitrogen), 0.2mM of each dNTP, 0.5mM
MgSO4, and 1U of Taq polymerase. Ampliﬁcation conditions
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consisted of an initial denaturation at 94C for 1min followed by
34 cycles of denaturation at 94C for 1min, annealing at 56.5C for
1min, and extension at 72C for 1min,with a ﬁnal extension step at
72c for 10min. The ampliﬁcation yielded distinct bands at 429 bp
(short ‘‘S’’ allele) and 549 bp (long ‘‘L’’ allele). For Dutch samples,
genotyping of the 120 bp tandem duplication polymorphism was
carried out using aPCR-basedmethod as described by Seaman et al.
[1999]. PCRwas performed on 62.5 ng genomicDNAusing 0.4mM
of each of the primers described above, 0.25mM dNTPs, 0.5U Taq
DNA polymerase (Invitrogen) in a PCR buffer containing 10mM
Tris–HCl pH 8.0, 50mM KCl, 0.1% Triton X-100 (v/v), 0.015%
gelatin (w/v), 5% DMSO (v/v), and 1.5mM MgCl2. The cycling
conditions were 10min 92C followed by 35 cycles of 1min 95C,
1min 58C, 1min 72C. At the end of the protocol, 10min at 72C
were added.
48 bp VNTR DRD4 polymorphism. Genotyping of the DRD4
48 bp VNTR polymorphism in exon 3 was performed according to
the method used by Johansson et al. [2008] for samples from
Norway and Spain. A protocol for PCR ampliﬁcation and fragment
analysis is available upon request. In short, DNAwas ampliﬁedwith
the following primers: 50-CGTACTGTGCGGCCTCAACGA-30
and FAM-50-GACACAGCGCCTGCGTGATGT-30. The reverse
primer was ﬂuorescently labeled and PCR products were visualized
on an ABI 3100 sequencer and automatically called using the
GeneMapper software (Applied Biosystems). All genotype calls
were also manually inspected. Analysis of the results using Gene-
mapper showed fragment length at 598 bp (2 repeats), 646 bp
(3 repeats), 694 bp (4 repeats), 742 bp (5 repeats), 790 bp
(6 repeats), 836 bp (7 repeats), 884 bp (8 repeats), 930 bp
(9 repeats), and 976 bp (10 repeats).
For the Dutch sample, the 48 bp repeat polymorphism was
analyzed by simple sequence analysis on a genetic analyzer using
primers as described earlier [Lichter et al., 1993]. For the PCR
ampliﬁcation, 50 ng of genomic DNA, 1.25mMﬂuorescent labeled
forward primer (50-Vic-GCGACTACGTGGTCTACTCG-30) and
1.25mM reverse primer with PIG tail (50-AGGACCCT-
CATGGCCTTG-30), 0.4mM dNTPs, 1 GCI Buffer TaKaRa
(Lucron Bioproducts BV, Gennep, The Netherlands), 0.5U Ta-
KaRa LA Taq (Lucron Bioproducts BV), and 1M betaine were
used. The cycling conditions were 1min 94C followed by 35 cycles
of 30 sec 94C, 30 sec 58C, 1min 72C, with a ﬁnal 5min step at
72C. The PCR product was diluted 10 times and 1ml of the diluted
PCR product together with 9.7ml formamide and 0.3ml GeneScan-
600 Liz Size StandaardTM (Applied Biosystems, Nieuwerkerk aan
de IJssel, TheNetherlands)was analyzedona3730GeneticAnalyzer
according to the protocol of the manufacturer. Analysis of the
results using Genemapper showed fragment length at 378 bp
(2 repeats), 426 bp (3 repeats), 474 bp (4 repeats), 522 bp
(5 repeats), 570 bp (6 repeats), 618 bp (7 repeats), and 666 bp (8
repeats).
For the German sample, PCR ampliﬁcation was performed using
Vent polymerase (New England Biolabs, Ipswich, MA) and a high
denaturing temperature (98C for 1min) with a combined anneal-
ing and extension reaction for 5min at 70C. The primers were 5’-
GCGACTACGTGGTCTACTCG-3’ and 5’-AGGACCCTCATG-
GCCTTG-3’. Thirty PCR cycles were performed and subsequently,
the reaction mixture was electrophoresed on a 2% Metaphor gel
(FMC) with ethidium bromide. The lengths of the resulting PCR
products are the same as describe above for the Dutch sample.
Statistical Analysis
Separate analysis of the four European samples. We ﬁrst
performed a single- and multiple-marker analysis on the samples
TABLE I. Descriptive Characteristics of the IMpACT Samples From Four European Countries









Female 307 (53.6) 248 (50.7) 325 (55.6) 245 (34.8) 1,125 (47.8) 872 (42.3) 813 (44.2) 845 (46.0)
Male 266 (46.4) 241 (49.3) 260 (44.4) 460 (65.2) 1,227 (52.2) 1,190 (57.7) 1,027 (55.8) 990 (54.0)
Total 573 (24.36) 489 (20.79) 585 (24.87) 705 (29.97) 2,352 2,062 1,840 1,835
Age (mean and SD) 30.73 (9.8) 63.46 (18.07) 27.4 (7.16)a 45.26 (14.79)
Cases
Female 304 (48.8) 119 (50.0) 215 (47.4) 82 (28.0) 720 (44.8) 644 (44.5) 613 (43.6) 537 (43.2)
Male 319 (51.2) 119 (50.0) 239 (52.6) 211 (72.0) 888 (55.2) 803 (55.5) 794 (56.4) 709 (56.8)
Total 623 (38.7) 238 (14.8) 454 (28.2) 293 (18.22) 1,608 1,447 1,407 1,246
Age (mean and SD) 33.91 (10.12) 41.23 (11.35) 33.9 (11.6) 36.02 (16.83)
ADHD subtype
Combined type 422 (68.3) 202 (86.0) 327 (72.03) 194 (66.2) 1,145 (71.2) 1,037 (71.7) 991 (70.4) 883 (71.0)
Inattentive type 151 (24.4) 24 (10.2) 47 (10.35) 87 (29.7) 309 (19.2) 279 (19.3) 275 (19.5) 243 (19.5)
Hyperactive/impulsive type 45 (7.3) 9 (3.8) 15 (3.30) 12 (4.1) 81 (5.04) 67 (4.6) 72 (5.1) 58 (4.7)
Sub-threshold — — 45 (9.91) — 45 (2.8) 44 (3.0) 45 (3.2) 44 (3.5)
Unknown — — 20 (4.41) — 20 (1.2) 20 (1.38) 20 (1.42) 16 (1.04)
aCalculated only for non-blood donors (n¼ 365).
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from the four IMpACT sites, separately, and then analyzed the
pooled sample using ameta-analytical approach.Hardy–Weinberg
equilibrium (HWE) in the control groups from each IMpACT
node as well as in the whole control sample was assessed
using a chi-squared test with the HWE software v.1.05
(www.linkage.rockefeller.edu/soft/linkutil). Genotype and allele
frequencies of the dup120bp and 48bpVNTR polymorphisms were
compared between cases and controls from each separate IMpACT
site using a chi-squared test with the SNPassoc R package and the
statistical package SPSS 15.0, respectively [Gonzalez et al., 2007].
Since the 48bpVNTR polymorphism is multiallelic (2R–11R
alleles), rare [minor allele frequency (MAF) <5%] genotypes and
alleles were grouped in a single class as ‘‘others.’’ Haplotype
frequencies were estimated using the PHASE software [Stephens
et al., 2001] and values below 5% were grouped as ‘‘others’’ in the
association analysis.
Meta-analysis. To combine the individual results, we con-
ducted a meta-analysis using the Meta R package (www.cran.r-
project.org/web/packages/meta/index.html). The analysis of the
minimal statistical power was performed post hoc using the
Genetic Power Calculator software (www.pngu.mgh.harvard.
edu/purcell/gpc), assuming a dominant model, an odds ratio
(OR) of 1.5, prevalence of 0.05, signiﬁcance level of 0.05 and aMAF
of 0.158 [Purcell et al., 2003]. We ﬁrst tested heterogeneity among
studies using the Q-statistic [Lau et al., 1997; Zintzaras and
Hadjigeorgiou, 2004]. When no heterogeneity was present, the
pooled OR was estimated using a ﬁxed-effects model [Mantel and
Haenszel, 1959]. A random-effect model was considered in those
caseswhere heterogeneitywasdetected [Laird andMosteller, 1990].
Meta-analysis was performed considering the whole ADHD
sample, but also split by gender or ADHD clinical subtypes. The
hyperactive-impulsive clinical sample couldnot be evaluateddue to
insufﬁcient sample size.
For the dup120bppolymorphism,wedetermined the best genetic
model tobeusedby estimating the threepossibleORs and their 95%
conﬁdence intervals (CI) in the meta-analysis sample: OR1 (SS vs.
LL), OR2 (SS vs. LS), and OR3 (LS vs. LL). If OR1¼OR3 „ 1 and
OR2¼ 1, then a recessive model is suggested; OR1¼OR2 „ 1 and
OR3¼ 1 indicates a dominant model and OR1>OR3> 1
(or OR1<OR2< 1 and OR1<OR3< 1) suggests a codominant
model. When none of the OR values signiﬁcantly deviated from 1,
then meta-analyses were performed for the three different genetic
models.
For the 48bpVNTRweminimizedmultiple-testing by restricting
the meta-analysis to alleles or genotypes showing frequency differ-
ences >3% among cases and controls in at least one of the study
populations. Thus, alleles 4R and 7R, and genotypes 4R4R, 4R7R,
and 7R7Rwere considered formeta-analysis. For the analysis of the
dup120bp/48bpVNTRhaplotypewe only considered the carriers of
the threemajor allelic combinations, S-4R, L-4R, and L-7R. The EH
software was used to test the presence of linkage disequilibrium
between the twoDRD4polymorphisms [Terwilliger andOtt, 1994].
DRD4 SLC6A3 interaction analysis. A logistic regression
analysis was used to evaluate the independent and interactive effects
of the DRD4 and SLC6A3 loci. For DRD4 we considered the
haplotype made up of the dup120bp L allele and the 4R allele of
the 48bpVNTR polymorphism (L-4R), while for the SLC6A3 gene
we considered the previously described risk haplotype comprising
the 9R allele of the VNTR in the 30UTR and the 6R allele of the
VNTR in intron8 (9R–6R), usingpre-existinggenotypedataonour
multicenter cohort of patients and controls [Franke et al., 2010]. A
stepwise logistic regression procedure was implemented to com-
pare two different regressionmodels by a likelihood ratio test using
the statistical package SPSS 15.0. In the ﬁrst model, we considered
the affection status as a dependent variable and the DRD4 and
SLC6A3 haplotypes as predictive variables. In the secondmodel, we
included the interaction DRD4 SLC6A3 as an independent
variable.
RESULTS
A total of 1,608 adult ADHD patients and 2,352 controls from four
IMpACT sites were genotyped for the DRD4 dup120bp and/or the
48bpVNTRpolymorphisms.The clinical descriptionof the samples
included in the study is shown in Table I.
Single-Marker Analysis
For the DRD4 dup120bp polymorphism, genotypes from 1,447
patients (90%) and 2,062 controls (88%) were available for the
single-marker analysis. No signiﬁcant departure from HWE was
observed, neither in the control group from each population nor in
the pooled sample (P> 0.05). No signiﬁcant association was de-
tected when we compared genotype and allele frequencies between
cases and controls from each separate site (Supplementary Table
SI). Stratiﬁcation of the ADHD samples according to gender or
clinical subtype in the four separate populations resulted in a
nominal association between the L allele of the dup120bp poly-
morphism and ADHD in males from Norway [P¼ 0.009,
OR¼ 1.69 (1.14–2.56); Supplementary Table SII]. Nominal asso-
ciation was also observed in two samples when we considered the
combined clinical subtype (Supplementary Table SIII): Norway
[P¼ 0.04, OR¼ 1.40 (1.01–1.96)] and Spain [P¼ 0.04, OR¼ 2.63
(0.91–7.69)]. The evaluation of the best geneticmodel for themeta-
analysis showed that none of the three ORs in the pooled sample
signiﬁcantly deviated from 1 [OR1(SS vs. LL)¼ 1.23 (95%CI:
0.82–1.84), OR2(SS vs. LS)¼ 1.23 (0.81–1.86), and OR3(LS vs. LL)¼
1.03 (95% CI: 0.88–1.20)] and, thus, we performed meta-analysis
considering the dominant, recessive, and codominant models.
However, no signiﬁcant association was found for dup120bp in
the full ADHD sample (Table II), or when patients were subdivided
bygender or clinical subtypes, in either of the threemodels (datanot
shown).
A total of 1,407 patients (87.5%) and 1,840 controls (78.2%) had
genotypes available for the DRD4 48bpVNTR polymorphism.
Genotype frequencies did not deviate signiﬁcantly from HWE in
any of the cohorts (P> 0.05). No signiﬁcant association between
the 48bpVNTR and ADHD was identiﬁed in any of the European
samples, when studied separately (Supplementary Table SIV). As
described above (Materials andMethods Section), only 4R/4R, 4R/
7R, and 7R/7R genotypes were available for the meta-analysis. No
association between the VNTR polymorphism and adult ADHD
was seen in the full ADHD sample (Table III), even if gender or
clinical subtypes were taken into account (data not shown).
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Multiple-Marker Analysis
Linkage disequilibriumbetween the two studied polymorphisms in
DRD4 was assessed and shown to be negligible (P¼ 0.99). Geno-
types from 1,246 patients (77%) and 1,835 controls (78%) were
available for the two DRD4 polymorphisms. Table IV summarizes
the estimated haplotype frequencies for the four populations
considered in the study. The comparison of haplotype frequencies
between cases and controls showed no association in any of the four
separate cohorts. We subsequently performed a meta-analysis
considering carriers of the three common DRD4 haplotypes,
S-4R, L-4R, and L-7R, and, after discarding the presence of
TABLE II. Genetic Effect of the DRD4 dup120bp Polymorphism on Adulthood ADHD
(a) Dominant model (LSþ LL vs. SS)
OR M-H, ﬁxed, 95% CI Study
Cases Controls
Weight (%) OR M-H, ﬁxed, 95% CI z P-valueSS Total SS Total
1. Germany 22 515 18 483 32.82 1.15 (0.61–2.17)
2. Netherlands 6 189 13 485 13.03 1.19 (0.44–3.17)
3. Norway 6 448 11 464 19.68 0.55 (0.20–1.52)
4. Spain 7 295 30 630 34.48 0.48 (0.20–1.12)
Fixed-effects model 41 1,447 72 2,062 100 0.81 (0.54–1.21) 1.02 0.30
Test of heterogeneity: Q¼ 3.74, df¼ 3, P¼ 0.29; I2¼ 19.7% (0–87.7%)
(b) Recessive model (LL vs. LSþ SS)
OR M-H, ﬁxed, 95% CI Study
Cases Controls
Weight (%) OR M-H, ﬁxed, 95% CI z P-valueLL Total LL Total
1. Germany 356 515 338 483 32.69 0.96 (0.73–1.25)
2. Netherlands 139 189 351 485 15.81 1.06 (0.72–1.55)
3. Norway 344 448 355 464 23.19 1.27 (0.94–1.71)
4. Spain 190 295 411 630 28.32 0.96 (0.72–1.28)
Fixed-effects model 1,029 1,447 1,455 2,062 100 1.05 (0.90–1.22) 0.63 0.52
Test of heterogeneity: Q¼ 2.36, df¼ 3, P¼ 0.50; I2¼ 0% (0–80.5%)
(c) Overdominant model (LS vs. LLþ SS)
OR M-H, ﬁxed, 95% CI Study
Cases Controls
Weight (%) OR M-H, ﬁxed, 95% CI z P-valueLS Total LS Total
1. Germany 137 515 127 483 30.13 1.01 (0.76–1.34)
2. Netherlands 44 189 121 485 16.30 0.91 (0.61–1.35)
3. Norway 98 448 118 464 28.36 0.82 (0.60–1.11)
4. Spain 98 295 189 630 25.21 1.16 (0.86–1.56)
Fixed-effects model 377 1,447 555 2,062 100 0.98 (0.83–1.14) 0.24 0.80
Test of heterogeneity: Q¼ 2.72, df¼ 3, P¼ 0.43; I2¼ 0% (0–83.1%)
S, short allele of the DRD4 dup120bp polymorphism (120bp); L, long allele of the DRD4 dup120 bp polymorphism (240 bp).
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heterogeneity between the four samples using the Q-statistic, we
observed an under-representation of the S-4R allelic combination
in the ADHD sample [P¼ 0.01; OR¼ 0.78 (0.65–0.95); Table IV].
We also performedmultiple comparisons stratifying by gender and
by clinical subtype and conﬁrmed these differences in females
[P¼ 0.04, OR¼ 0.73 (0.54–0.99); Supplementary Table SV].
Interestingly, when we considered patients with the ADHD
combined subtype only, we observed an increased frequency of
carriers of the L-4R risk haplotype [P¼ 0.02; OR¼ 1.29
(1.04–1.61)] in addition to an under-representation of the S-4R
TABLE III. Genetic Effect of the DRD4 48bpVNTR Polymorphism on Adulthood ADHD
(a) Comparison of the 4R4R genotype versus others
OR M-H, ﬁxed, 95% CI Study
Cases Controls
Weight (%) OR M-H, random, 95% CI z P-value4R4R Total 4R4R Total
1. Germany 200 436 63 156 20.98 1.25 (0.86–1.81)
2. Netherlands 102 236 193 476 24.39 1.11 (0.81–1.53)
3. Norway 179 449 190 488 28.12 1.03 (0.79–1.35)
4. Spain 109 289 290 631 26.51 0.71 (0.53–0.94)
Fixed-effects model 590 1,410 736 1,751 100 0.97 (0.84–1.13) 0.27 0.78
Test of heterogeneity: Q¼ 7.34, df¼ 3, P¼ 0.06; I2¼ 59.1% (0–86.4%)
(b) Comparison of 7R7R genotypes versus others
OR M-H, ﬁxed, 95% CI Study
Cases Controls
Weight (%) OR M-H, ﬁxed, 95% CI z P-value7R7R Total 7R7R Total
1. Germany 29 436 7 156 16.90 1.41 (0.60–3.30)
2. Netherlands 8 236 24 476 26.53 0.66 (0.29–1.19)
3. Norway 20 449 26 488 41.20 0.82 (0.45–1.49)
4. Spain 16 289 15 631 15.37 2.40 (1.17–4.93)
Fixed-effects model 73 1,410 72 1,751 100 1.12 (0.78–1.59) 0.63 0.52
Test of heterogeneity: Q¼ 7.29, df¼ 3, P¼ 0.06; I2¼ 58.9% (0–86.3%)
(c) Comparison of the 4R7R genotypes versus others
OR M-H, random, 95%% CI Study
Cases Controls
Weight (%%) OR M-H, random, 95%% CI z P-value4R7R Total 4R7R Total
1. Germany 89 436 37 146 23.0 0.75 (0.48–1.17)
2. Netherlands 50 236 121 335 24.34 0.47 (0.32–0.69)
3. Norway 124 429 136 488 21.64 1.19 (0.90–1.58)
4. Spain 85 289 157 631 24.72 1.25 (0.92–1.71)
Fixed-effects model 348 1,390 451 1,600 100 0.87 (0.56–1.35) 0.61 0.53
Test of heterogeneity: Q¼ 19.3, df¼ 3, P¼ 0.0002; I2¼ 84.5% (61.1–93.8%)
4R: 4 repeats of the DRD4 48bpVNTR polymorphism; 7R: 7 repeats of the DRD4 48bpVNTR polymorphism.
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allelic combination [P¼ 0.01 OR¼ 0.75 (0.60–0.94)] in this clini-
cal dataset (Table V).
Interaction Between DRD4 and SLC6A3
Since we previously described an association of adulthood ADHD
with the SLC6A3 9R-6R haplotype (30UTRVNTR-intron 8 VNTR)
in the same dataset [Franke et al., 2010], we further tested for
gene gene interactions between the ADHD-associated haplo-
types of DRD4 and SLC6A3. Genotypes from 1,208 patients
(75%) and 1,290 controls (55%) were available for the four poly-
morphisms in the two genes. Although no evidence for epistatic
effects was detected, the simultaneous presence of the two risk
haplotypes, DRD4 L-4R and SLC6A3 9R-6R, increased the risk
for ADHD in both the ADHD sample as a whole [P¼ 3.04e–05;
OR 1.66 (1.31–2.11)] and in the combined clinical subtype
[P¼ 2.66e–05; OR¼ 1.74 (1.35–2.26)]. Thus, the OR for ADHD
subjects carrying the DRD4 L-4R haplotype rose from 1.09
(0.90–1.32) to 1.66 (1.31–2.11) in those patients also carrying the
SLC6A3 9R-6R allelic combination. Similar resultswere obtained in
the combined type ADHD clinical subtype (Fig. 1) and indicate
additive effects between risk haplotypes at these two loci.
DISCUSSION
In the present study we performed ameta-analysis in a large sample
of 1,608 adulthood ADHD patients and 2,352 unrelated controls
from four European countries to evaluate the role of the DRD4
dup120bp and 48bpVNTR polymorphisms in the persistent form
of the disorder. Although nominal association with dup120bp was
observed in some of the populations considered in this study, no
evidence for a role of either polymorphism in ADHD was detected
when they were considered separately in the entire sample. The
multiple-marker analysis, however, supports a contribution of the
L-4R (dup120bp-48bpVNTR) haplotype to adulthood ADHD,
mainly to the combined clinical subtype, although these ﬁndings
should be viewed with caution given the many (albeit highly
correlated) statistical tests performed. These results support a
connection between DRD4 and the persistence of the ADHD
symptoms across the life span, in line with previous follow-up
studies [Biederman et al., 2009].
Many association studies between DRD4 and ADHD have been
performed, although results are often controversial. In this regard,
although our data in the single-marker analysis are in agreement
with previous reports showing no association between ADHD and
the 48bpVNTR polymorphism [Roman et al., 2001; Todd et al.,
2001; Bakker et al., 2005; Brookes et al., 2005; Carrasco et al., 2006;
Johansson et al., 2008; Sonuga-Barke et al., 2008], they are contrary
to others having reported on association between the 7R allele and
the disorder [Rowe et al., 1998; Faraone et al., 2001; Maher et al.,
2002; Wohl et al., 2005; Brookes et al., 2006; Li et al., 2006; Gizer
et al., 2008, 2009; Biederman et al., 2009; Langley et al., 2009;
Nikolaidis and Gray, 2010]. Likewise, our results for the DRD4
dup120bp polymorphism are in line with most of the literature,
including a recentmeta-analysis [Barr et al., 2001; Todd et al., 2001;
Mill et al., 2003; Kirley et al., 2004; Brookes et al., 2005; Bhaduri
et al., 2006; Gizer et al., 2009], but not with ﬁndings from the ﬁrst
two association analyses of this variation [McCracken et al., 2000].
Due to the heterogeneity of populations, methodologies and
statistical tests used, it is difﬁcult to establish direct comparisons
between all these reports. In the case of the 48bpVNTR, allele
frequencies of this multiallelic polymorphism vary considerably
across ethnic groups. The 4R allele is the most prevalent one
and appears in all populations. However, 7R is frequent among
Americans but rare among Asians and 2R is frequent in Asia but
uncommon among Americans [Van Tol et al., 1992; Chang et al.,
1996;Ding et al., 2000;Wang et al., 2004]. In addition, some studies
collapse different alleles into long and short categories (6R–8R vs.
2R–5R) [Eisenberg et al., 2000; Manor et al., 2002] and others only
consider the most frequent alleles among Caucasians (4R and 7R)
[Roman et al., 2001; Bellgrove et al., 2005]. Because grouping
several frequent alleles in a single category or considering only
TABLE IV. Pooled Analysis Considering S-4R Carriers of the DRD4 dup120bp-48bp VNTR Haplotype in 1,246 Adulthood ADHD Patients and
1,835 Controls
OR M-H, ﬁxed, 95% CI Study
Cases Controls
Weight (%) OR M-H, ﬁxed, 95% CI z P-valueS-4R Total S-4R Total
1. Germany 60 327 33 120 16.69 0.59 (0.65–0.96)
2. Netherlands 32 187 99 478 19.53 0.79 (0.50–1.22)
3. Norway 67 443 91 544 29.34 0.88 (0.62–1.25)
4. Spain 62 289 176 693 34.44 0.80 (0.57–1.11)
Fixed-effects model 221 1,246 399 1,835 100 0.78 (0.65–0.95) 2.39 0.01
Test of heterogeneity: Q¼ 1.78, df¼ 3, P¼ 0.62; I2¼ 0% (0–74.1%)
S, short allele of the dup120bp polymorphism (120 bp); 4R, 4 repeats of the 48bpVNTR polymorphism.
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variants described in previous analyses may result in loss of crucial
genetic information, we included all frequent alleles separately and
grouped the less frequent variants (<5%) into a single group.
Several other explanations could also account for the inconsis-
tent ﬁndings observed among previously reported DRD4 studies.
Differences in sample size, comorbidities, and proportions of
clinical subtypes or genders may result in discordant results.
Limited sample sizes may provide imprecise or incorrect estimates
of themagnitude of the observed effects. The present meta-analysis
provides an adequate statistical power (>99%) to detect an associ-
ation of small effect. Additionally, in the case of gender-speciﬁc
associations, differences in the male:female proportion among
studies may also contribute to variability. In this regard, although
nominal and site-speciﬁc, we found male-speciﬁc association sig-
nals in the Norwegian sample when samples were stratiﬁed accord-
ing to gender. Whether the different ADHD clinical subtypes share
genetic risk factors has been still poorly explored. The association
between ADHD and the DRD4 risk haplotype detected in the
present study was observed in the combined but not in the
inattentive clinical subtype. Our results are in agreement with
previous studies supporting the validity of the different DSM-IV
subtypes, mainly the combined subtype, and suggesting the
participation of differential genetic factors in distinct ADHD
clinical groups [Rasmussen et al., 2004; Larsson et al., 2006;
Sobanski et al., 2008; Ribases et al., 2009]. Interestingly, Smith
[2010] performed ameta-analysis of 28 association studies between
ADHD and the 48bpVNTR inDRD4 and observed that increases in
the proportion of combined ADHD patients within an ADHD
sample were associated with an increase in the magnitude of the
effect. These results are consistent with the hypothesis thatDRD4 is
more strongly associated with combined ADHD than with inatten-
tiveADHDandare in linewith thehypothesis that hypofunctioning
in mesocortical and mesolimbic dopaminergic pathways better
characterize the etiology of combined ADHD than inattentive
ADHD[Sagvolden et al., 2005; Smith, 2010]. This view is supported
by the fact that variation in DAT1, another dopaminergic gene, is
also more strongly associated with combined ADHD than with
inattentive ADHD (e.g., Waldman et al., 1998). Moroeover, it is
possible that consideration of neuropsychological traits, comor-
bidities or personality data, not included in the present study, may
help in the future to obtain better association signals with DRD4
than the analysis of the sole ADHDcondition. Finally, sincemost of
TABLE V. Pooled Analysis Considering the (a) S-4R and (b) L-4R Carriers of the DRD4 dup120bp-48bpVNTR Haplotype in 788 Combined
ADHD Patients and 1,835 Controls
(a) S-4R
OR M-H, ﬁxed, 95% CI Study
Cases Controls
Weight (%) OR M-H, ﬁxed, 95% CI z P-valueS-4R Total S-4R Total
1. Germany 41 204 33 120 18.12 0.66 (0.39–1.12)
2. Netherlands 30 168 99 478 23.08 0.83 (0.52–1.30)
3. Norway 34 231 91 544 25.25 0.85 (0.56–1.31)
4. Spain 36 190 176 693 33.54 0.68 (0.45–1.02)
Fixed-effects model 140 788 399 1,835 100 0.75 (0.60–0.94) 2.42 0.01
Test of heterogeneity: Q¼ 0.98, df¼ 3, P¼ 0.80; I2¼ 0% (0–53.2%)
(b) L-4R
OR M-H, ﬁxed, 95% CI Study
Cases Controls
Weight (%) OR M-H, ﬁxed, 95% CI z P-valueL-4R Total L-4R Total
1. Germany 153 204 93 120 20.27 0.87 (0.51–1.48)
2. Netherlands 130 168 366 478 29.82 1.04 (0.68–1.59)
3. Norway 196 226 422 544 22.77 1.88 (1.22–2.91)
4. Spain 158 190 540 693 27.13 1.38 (0.91–2.11)
Fixed-effects model 637 788 1,421 1,835 100 1.29 (1.04–1.61) 2.31 0.02
Test of heterogeneity: Q¼ 6.14, df¼ 3, P¼ 0.10; I2¼ 51.1% (0–83.8%)
S, short allele of the dup120bp polymorphism (120 bp); L, Long allele of the dup120bp polymorphism (240 bp); 4R, 4 repeats of the 48bpVNTR polymorphism.
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previous research on the DRD4 gene has focused on childhood
patients (only four studies having considered the 48bpVNTR
polymorphism in adulthood ADHD [Muglia et al., 2000; Smith
et al., 2003; Boonstra et al., 2008; Johansson et al., 2008], differential
proportion of remitting and persisting ADHD within the children
samples may also explain discordant results among studies
[Brookes et al., 2006; Gornick et al., 2007; Langley et al., 2009].
In this regard, Shaw et al. [2007] showed in a longitudinal study that
the 7R allele was associated with a better clinical outcome and with
differences in cortical thickness in regions that are important in
attention control. These neuroanatomical changes were most ap-
parent early in development and resolved by late adolescence. In
addition, Johansson et al. [2008] showed a trend towards protective
effects of the 7R allele in adults with ADHD, results that suggest a
different effect of the 7R allele in child and adulthood ADHD and
could explain previous controversial results. However, another
recent study by Biederman et al. [2009] showed increased risk of
ADHD persistence due to the 7R allele.
The identiﬁcation of different alleles at the same markers as
susceptibility factors for ADHD in several studies and the failure to
consistently replicate positive associations suggest that the
dup120bp and the 48bpVNTR polymorphisms may not be
themselves the causative variants that increase disease risk but are
in linkage disequilibrium with a true causative variant within the
same gene. Further deep-sequencing of this genomic region may
allow identiﬁcation of the functional DRD4 variants directly in-
volved in the genetic background of ADHD. In that regard, it is
interesting tonote that an increasedburdenof rare variants hasbeen
observed in the 7R allele of DRD4 in children with ADHD [Grady
et al., 2003].
In addition, we detected preliminary evidence of additive, but
not epistatic, effects for DRD4 and SLC6A3 in ADHD. Since
SLC6A3 is expressed in subcortical regions whereas DRD4 is ex-
pressed in frontal cortex, the two genes may indeed be expected to
increaseADHDrisk by acting in independent pathways [Durston et
al., 2005]. However, it is difﬁcult to draw a ﬁnal conclusion about
the combined participation of these two genes in ADHD symp-
tomatology as several studies have described discordant results
[Roman et al., 2001; Kim et al., 2005; Carrasco et al., 2006; Qian
et al., 2007; Gabriela et al., 2009].
In summary, the results of the present study showed nominal
association between the L-4R haplotype (dup120bp-48bpVNTR)
and adulthood combined ADHD through a meta-analysis of four
European populations. Our results also suggest an additive effect
between this DRD4 risk haplotype and SLC6A3. Replication in
other datasets is warranted to conﬁrm these results and to better
understand the involvement of theDRD4 and SLC6A3 genes in the
predisposition to the persistent form of ADHD.
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